Search

Your search keyword '"Gordon, Michael. S."' showing total 1,196 results

Search Constraints

Start Over You searched for: Author "Gordon, Michael. S." Remove constraint Author: "Gordon, Michael. S."
1,196 results on '"Gordon, Michael. S."'

Search Results

1. Submillimeter-wavelength Polarimetry of IRC+10216

4. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

5. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid TumorsDilpacimab in Patients with Advanced Solid Tumors

6. On the collisional disalignment of dust grains in illuminated and shaded regions of IC 63

7. Red Supergiants, Yellow Hypergiants, and Post-RSG Evolution

8. Exploring the Mass Loss Histories of the Red Supergiants

9. Continuing Care App for Probationers and Parolees with Substance Use Disorders

10. ALMA polarimetry measures magnetically aligned dust grains in the torus of NGC 1068

11. The Unexpected Spectrum of the Innermost Ejecta of the Red Hypergiant VY CMa

12. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

13. Luminous and Variable Stars in NGC 2403 and M81

14. Thermal Emission in the Southwest Clump of VY CMa

16. A Tale of Two Impostors: SN2002kg and SN1954J in NGC 2403

18. Searching for Cool Dust: II. Infrared Imaging of the OH/IR Supergiants, NML Cyg, VX Sgr, S Per and the Normal Red Supergiants RS Per and T Per

19. Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.

20. Phase II clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer.

21. Massive Star Formation in the LMC. I. N159 and N160 Complexes

22. Luminous and Variable Stars in M31 and M33. IV. Luminous Blue Variables, Candidate LBVs, and the B[e] Supergiants; How to Tell Them Apart

23. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

24. Submillimeter-wavelength Polarimetry of IRC+10216

25. Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C) and hydroxychloroquine (HCQ) neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).

26. Multiple Outflows in the Giant Eruption of a Massive Star

27. Luminous and Variable Stars in M31 and M33. III. The Yellow and Red Supergiants and Post-Red Supergiant Evolution

28. On the Social Traits of Luminous Blue Variables

29. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

30. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

31. A New Luminous Blue Variable in M31

33. 756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

34. 594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+tumors treated with cell-based vaccine, SQZ-PBMC-HPV

35. 692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors

36. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

39. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

40. The Atacama Cosmology Telescope: Cosmological parameters from three seasons of data

44. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations

46. A Sample of Candidate Radio Stars in FIRST and SDSS

47. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.

48. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

Catalog

Books, media, physical & digital resources